Kelly A. Avery-Kiejda

Medical Genetics, Hunter Medical Research Institute

Affiliated withHunter Medical Research Institute University of Newcastle

Research Area

Biography

Kelly A. Avery-Kiejda has not added Biography.
If you are Kelly A. Avery-Kiejda and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 17	2016
Publication title Cited by 1	2019

Other Publications

Article	Year
Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anti-cancer drugs\| PubMed ID: 18176116	2008
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18310316	2008
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer research\| PubMed ID: 18701495	2008
Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis\| PubMed ID: 18842681	2009
Nucleotide excision repair gene expression after Cisplatin treatment in melanoma. Cancer research\| PubMed ID: 20807809	2010
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast cancer research and treatment\| PubMed ID: 21409391	2011
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC cancer\| PubMed ID: 21615965	2011
Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer. International journal of cancer\| PubMed ID: 23824750	2014
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma. PloS one\| PubMed ID: 23940574	2013
STaRRRT: a table of short tandem repeats in regulatory regions of the human genome. BMC genomics\| PubMed ID: 24228761	2013
The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis\| PubMed ID: 24336193	2014
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC cancer\| PubMed ID: 24479446	2014
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer. BMC cancer\| PubMed ID: 24725360	2014
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nature communications\| PubMed ID: 25641231	2015
Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis. Molecular & cellular proteomics : MCP\| PubMed ID: 26041846	2015
Novel genes associated with lymph node metastasis in triple negative breast cancer. Scientific reports\| PubMed ID: 26537449	2015
The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome. Carcinogenesis\| PubMed ID: 26586794	2016
MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. International journal of molecular sciences\| PubMed ID: 26633365	2015
A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer. Endocrine connections\| PubMed ID: 27090263	2016
A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer. BMC research notes\| PubMed ID: 27230222	2016
The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer. Breast cancer research and treatment\| PubMed ID: 30430302	2018